Table 1. Clinical characteristic of overall patients.
| Clinical parameters | Value |
|---|---|
| Total number | 40 |
| Sex (female), n (%) | 28 (70.0) |
| Age (years), median [range] | 61.5 [40–82] |
| Pathologic type, n | |
| Adenocarcinoma | 40 (only type studied) |
| Driver mutations, n (%) | |
| EGFR mutation | 36 (90.0) |
| 19 deletion | 22 (61.1) |
| 21 L858R | 12 (33.3) |
| Subtype not available | 2 (5.6) |
| ALK translocation | 4 (10.0) |
| PD-L1 expression (at diagnosis) SP263 (n=27), n (%) | |
| 0% | 12 (30.0) |
| 1–9% | 5 (12.5) |
| 10–49% | 5 (12.5) |
| 0–99% | 5 (12.5) |
| Clinical stage at diagnosis, n (%) | |
| Stage I–II | 3 (7.5) |
| Stage III | 12 (30.0) |
| Stage IV | 25 (62.5) |
| Smoking history, n (%) | |
| Never smoker | 28 (70.0) |
| Ever smoker | 12 (30.0) |
| Targeted therapy prior to surgery†, n (%) | |
| Afatinib | 20 (50.0) |
| Alectinib | 3 (7.5) |
| Brigatinib | 1 (2.5) |
| Dacomitinib | 1 (2.5) |
| Erlotinib | 5 (12.5) |
| Gefitinib | 3 (7.5) |
| Lazertinib | 1 (2.5) |
| Osimertinib | 7 (17.5) |
| Duration of prior TKI treatment (months), median [range] | 18.0 [2.6–68.6] |
| Clinical stage at initiation of TKI, n (%) | |
| Stage III | 9 (22.5) |
| Stage IV | 31 (77.5) |
| Clinical stage at resection, n (%) | |
| Stage II | 1 (2.5) |
| Stage III | 9 (22.5) |
| Stage IV | 29 (72.5) |
| Downstaged (TNM 8th), n (%) | 3 (7.5) |
| Unchanged (TNM 8th), n (%) | 34 (85.0) |
| Upstaged (TNM 8th), n (%) | 2 (5.0) |
| ECOG at resection, n (%) | |
| 0 | 28 (70.0) |
| 1 | 10 (25.0) |
| 2 | 2 (5.0) |
†, one patient had undergone two targeted therapy regimens before resection. EGFR, epidermal growth factor receptor; ALK, anaplastic lymphoma kinase; PD-L1, programmed death-ligand 1; TKI, tyrosine kinase inhibitor; TNM, tumor, node, metastasis; ECOG, Eastern Cooperative Oncology Group.